ID Name Structure References (top 5) Molecular Target(s)
1ID:6536
URACIL


Aldrich#:130788
Aldrich#:333778
Aldrich#:37950
Aldrich#:486264
Aldrich#:94220
Aldrich#:U0750
Aldrich#:U1128
Aldrich#:U3879

Freqency:
in 1 ingredients:

  • 484
  • in 14 recipes:

  • 8
  • 10
  • 17
  • 21
  • 23
  • 30
  • 43
  • 53
  • 109
  • 117
  • 123
  • 178
  • 180
  • 184

  • Properties
    C4H4N2O2    112.09





    1:  Reader JS, Joyce GF.
    A ribozyme composed of only two different nucleotides.
    Nature.    impact factor:   29.491
    2002;  420(6917): 841-4

    2:  Karahalil B, Hogue BA, de Souza-Pinto NC, Bohr VA.
    Base excision repair capacity in mitochondria and nuclei: tissue-specific variations.
    FASEB J.    impact factor:   11.88
    2002;  16(14): 1895-902

    3:  Gilbert MT, Hansen AJ, Willerslev E, Rudbeck L, Barnes I, Lynnerup N, Cooper A.
    Characterization of genetic miscoding lesions caused by postmortem damage.
    Am J Hum Genet.    impact factor:   10.426
    2003;  72(1): 48-61

    4:  Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR.
    Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
    Cancer Res.    impact factor:   8.614
    2002;  62(23): 6909-15

    5:  Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S.
    Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205).
    J Clin Oncol.    impact factor:   7.963
    2003;  21(1): 54-9

     
    Time used: 437 milliseconds.

    Webpage designed by Dr. Xueliang Fang, last updated on 3/10/2005